SLI & Pulmonary HA Deposition After SAH
- Conditions
- Subarachnoid Haemorrhage (SAH)
- Registration Number
- NCT06628531
- Lead Sponsor
- Tianjin Medical University
- Brief Summary
Acute lung injury is a common complication of subarachnoid hematoma (SAH), and a significant risk factor for death in patients with SAH. Unlike neurogenic pulmonary edema and pneumonia following brain injury, the clinical causes of pulmonary injury after SAH are not intracranial hypertension or pulmonary infection. Its occurrence is influenced by the release of catecholamines, the regulatory function of the hypothalamic-pituitary-adrenal (HPA) axis and systemic inflammatory response, but the specific mechanisms are still unclear. Therefore, delving into the pathological mechanisms of SAH-induced lung injury and developing therapeutic strategies based on the findings is of great importance to improve the prognosis of patients.
Abnormal accumulation of hyaluronic acid in the lungs has been reported to be closely related to the pathological progression of various pulmonary injury diseases, such as chest trauma, pulmonary infection and chronic obstructive pulmonary disease. From this, the present research is aimed to explore the levels and dynamic changes of hyaluronic acid in the bronchoalveolar lavage fluid and blood of patients with acute lung injury following SAH, and to analyze its correlation with the prognosis of pulmonary complications, thereby providing assistance for the clinical diagnosis and treatment of SAH.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 24
- Age between 18 and 80 years old with independent behavior ability or authorized legal representative.
- A documented diagnosis of SAH within 5 days.
- A Hunt-Hess scale of Ⅳ or Ⅴ.
- Absence of clinical and etiological evidence of pulmonary infection.
- Pregnant or lactating women.
- Present history of traumatic brain injury or intracranial hemorrhage.
- Past history of neurological disorders, lung infection within the past six months, cancer, chronic cardiopulmonary diseases, hematological diseases or renal failure.
- Have participated in clinical trials in the past 4 weeks.
- The investigator considers that not appropriate for inclusion.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hyaluronic acid level in bronchoalveolar lavage fluid after SAH During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH Hyaluronic acid level (ng/ml) in bronchoalveolar lavage fluid at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Inflammatory cytokines levels in bronchoalveolar lavage fluid after SAH During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH Inflammatory cytokines (IL-1β, TNF-α and IL-10) levels (pg/ml) in bronchoalveolar lavage fluid at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
- Secondary Outcome Measures
Name Time Method Serum hyaluronic acid level after SAH During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH Serum hyaluronic acid level (ng/ml) at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Serum inflammatory cytokines levels after SAH During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH Serum inflammatory cytokines (IL-1β, TNF-α and IL-10) levels (pg/ml) at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Trial Locations
- Locations (1)
Tianjin Medical University General Hospital
🇨🇳Tianjin, China